EE186 Cost per Responder of TAR-200 vs. Other FDA-Approved Novel and Generic Treatments Among Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ in the United States
Abstract
Authors
Stephen Williams Sang Cho Laura Morrison Mukul Singhal Dominic Pilon Kayleen Gwyn Beatrice Libchaber Gordon Wong Francesca Lee Urvi Desai Kruti Joshi